of any given individual is determined by the total serum concentration of pro-hormone 25-hydroxyvitamin D (25D) (2) . However, this parameter remains controversial with target levels for circulating 25D varying considerably depending on the population and clinical endpoint being studied (3, 4) . It is also unclear how total serum 25D levels relate to physiological or disease responses given that 25D is an inactive form of vitamin D that must be metabolized to active 1,25-dihydroxyvitamin D (1,25D) to initiate transcriptional responses via the nuclear vitamin D receptor (VDR). This may be particularly important for the many non-classical, extra-skeletal effects of 1,25D that have been reported in recent years (5) (6) (7) (8) , where conversion of 25D to 1,25D and subsequent VDR signaling may take place in a tissue-specific manner (9) .
In serum, vitamin D metabolites are bound primarily to the serum vitamin D binding (DBP) (10, 11) . This association is central to the reabsorption of 25D in the proximal nephron and its subsequent metabolism to active 1,25D (1,25D) via the enzyme 1α-hydroxylase (CYP27B1) (12, 13) , but binding to DBP does not appear to underpin the entry of 25D into many other tissues. Instead, for most extra-renal tissues the general assumption is that vitamin D metabolites are biologically active when they are free of serum binding, even though this fraction may be very small (11, 14) . This is likely to be crucial to vitamin D physiology because of the widespread extra-renal expression of CYP27B1 (15) , where localized synthesis of 1,25D and associated VDR responses may be highly dependent on the tissue availability of 25D that is not bound to DBP (16) . The so-called 'free-hormone hypothesis' (17,18) has questioned the validity of total serum 25D measurement as an accurate marker of vitamin D function (19), and revived interest in DBP as a pivotal component of vitamin D physiology.
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Genome-wide association studies have underlined the link between DBP genotype, circulating levels of DBP and serum 25D status (20) . However, studies of Dbp knockout mice showed that although these mice had almost undetectable serum levels of total 25D, the mice were phenotypically normal when raised on a normal vitamin D diet (21). A potential explanation for this is that despite lower circulating levels of total 25D, Dbp-/-mice have similar serum concentrations of free 25D relative to wild type mice. With this observation in mind, we developed an alternative strategy for comparing the relative importance of total vs free serum 25D based on the differential binding affinity of vitamin D metabolites for DBP. Previous studies have shown that relative to 25D3, 25D2 has a lower binding affinity for DBP (22) (23) (24) ). This appears to be a key factor in the decreased serum half-life of 25D2 compared to 25D3 (25), and the increasing reluctance to use vitamin D2 for supplementation studies (26). To further characterize the relative impact of these two forms of 25D on physiological responses in vivo, we utilized mouse models where animals were raised from weaning on diets containing exclusively vitamin D2 or vitamin D3.
Materials and Methods
Cell culture. Studies in vitro were carried out using the MG63 human osteoblast cell line (ATCC, Manassas, VA) cultured in DMEM medium with 10% fetal bovine serum and incubated at 37 o C. For dose response to 25D2/D3 studies, cells were incubated in 2% human serum (HS) or 10% bovine serum albumin (BSA) for 6 hrs. After treatment, media was removed and TRIzol was added to extract RNA, cDNA was generated by Super Script III Reverse Transcriptase with random primers according to suggested manufacturer procedures. RT-PCR was used to amplify cDNA and quantify genes of interest. Cycle threshold values were determined by instrument software for genes of interest and were subtracted by the cycle threshold values of 18S rRNA to yield Ct values. Data is expressed as Ct relative to vehicle treated cultures. were allocated to D2 and D3 mice, with sample size based on previous studies of vitamin Dsufficient and deficient mice (27). Each animal was an experimental unit, but mice were housed four animals per cage and entry into the study was staggered so that only eight mice were sacrificed on any given week. For serum vitamin D metabolites, bone histomorphometry and spleen immune cell and gene expression studies, samples were analyzed blind. The primary outcome of this approach was to assess total and free serum concentrations of 25D2 and 25D3, with secondary outcomes being changes in bone and spleen markers.
Mice were housed within the CHS B-Floor mouse only barrier Specific Pathogen-Free facility at UCLA that utilizes static micro-isolator and ventilated racks with beta chip and/or corn cob bedding material for mouse cages. All operations staff were dedicated to this facility only. Mice received D2-or D3-specific chow, and filtered tap water was provided via water bottles. Investigators had direct access to the mice, and all manipulations were carried out in a cage change station. Investigators provided fresh diet on a twice-weekly basis (Monday and Friday). Vivarium staff changed water and bedding weekly and, along with investigators, observed mice for general health and well-being. Automatic light cycles (12 light/12 dark) are installed in all animal holding rooms along with 24/7 room environment monitoring devices. and error bars in graphs were standard deviation (SD) or SEM as indicated in figure legends.
Results

Differential potency of 25D2 and 25D3 in vitro
Consistent with previous studies of human monocytes (16), analysis of MG63 osteoblastic cells in vitro showed that these cells were more sensitive to 25D (25D2 or 25D3) when cultured in the medium lacking serum (2% human serum, 2% HS) (Figure 1) . Furthermore, MG63 cells cultured in 2% HS showed greater sensitivity to 25D2 relative to 25D3 when measuring induction of the mRNA for osteocalcin (OC) ( Figure 1A ). However, both 25D2 and 25D3 were equally effective in stimulating OC mRNA when MG63 cells were cultured in serum-free medium ( Figure 1B ). These data supported the over-arching hypothesis that 25D2 has greater biological potency in the presence of serum proteins such as DBP.
Serum free 25D is elevated in mice raised on vitamin D2 diet relative to vitamin D3
To assess possible variations in functionality of 25D2 and 25D3 in vivo, further studies were carried out using mice raised on diets containing either vitamin D2 (D2) or vitamin D3 (D3) only.
These diets had no detrimental effect on mice at 8 or 16 wks of age, and each group of animals exhibited circulating 25D that was exclusively 25D2 or 25D3, with corresponding serum 1,25D2 or 1,25D3. In D2 mice, serum concentrations of 25D2 (26.56 ± 1.88 ng/ml at 8 wks and 33.25 ± 4.38 ng/ml at 16 wks) were similar to serum concentrations of 25D3 in D3 mice (28.27 ± 2.01 ng/ml at 8 wks and 31.72 ± 2.06 ng/ml at 16 wks) (Figure 2A ). For both D2 and D3 mice, serum concentrations of 25D2 or 25D3 were significantly higher at 16 wks of age compared to 8 wks.
In a similar fashion, serum concentrations of 1,25D2 and 1,25D3 were higher in wk 16 mice compared to wk 8 mice. However, in both age groups serum concentrations of 1,25D3 in D3 mice (62.38 ± 11.59 pg/ml at 8 wks and 95.53 ± 11.59 pg/ml at 16 wks), were significantly higher than serum 1,25D2 in D2 mice (44.49 ± 6.45 pg/ml at 8 wks and 78.42 ± 12.61 pg/ml at 16 wks) ( Figure 2B ). Measurement of DBP concentrations for week 8 serum samples showed no significant difference between D2 and D3 mice ( Figure 2C ). Despite this, free 25D levels were higher in D2 mice relative to D3 mice (16.75 ± 0.65 pg/ml vs 8.40 ± 0.63 pg/ml at 8 wks and 17.38 ± 0.43 ng/ml vs 8.43 ± 0.44 pg/ml at 16 wks) ( Figure 2C ).
Differences in kidney gene expression in D2 versus D3 mice
Analysis of kidney tissue showed no significant effect of D2 or D3 diets on expression of mRNA 
Variations in bone structure and cell composition in D2 versus D3 mice
Histomorphometric analysis of femurs from D2 and D3 mice showed changes in bone structure that were sex, diet, and time-related. Example histomorphometric analyses for femur bone from wk16 female mice on D2 or D3 diets are shown in Figure 5 . Quantitative analysis of bone structure markers was carried out for femur sections from multiple mice using defined regions of interest ( Figure 5 inset box) with resulting data shown in Table 1 . Statistically significant differences in bone structure and turnover markers for wk8 mice were primarily due to sex, with Histomorphometric analyses for bone bone-resorbing osteoclasts (Oc) and bone-forming osteoblasts (Ob) was also carried out, as illustrated by the example femurs from wk8 female mice in shown in Figure 7 . Quantitative analysis of these data using femur sections from wk8
and wk16 mice is shown in Table 2 . In wk8 mice the primary factor influencing these markers where there was no significant difference in serum total 25D concentrations for D2 versus D3 mice at wk8 or wk16. However, there was a trend towards higher serum concentrations of 1,25D in D3 mice (although this was only statistically significant in wk8 male mice), suggesting a greater conversion rate of 25D3 to 1,25D3, relative to the rate of conversion of 25D2 to 1,25D2.
Previous studies have shown that there is no preferential metabolism of 25D2 to 1,25D2 vs
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25D3 to 1,25D3 (33) although, in contrast to the current study, this particular analysis involved human subjects with a combination of D2 and D3 circulating metabolites.
The elevation of serum 1,25D in wk16 D3 mice relative to D2 mice may occur through better recovery of substrate for the proximal tubule 1α-hydroxylase enzyme via megalin-mediated glomerular reabsorption of the 25D3-DBP complex (12) . The difference does not appear to be due to differential kidney expression of the enzyme 1α-hydroxylase, as analysis of renal mRNA for Cyp27b1 showed no difference between D2 and D3 mice. In a similar fashion, expression of renal mRNA for Cyp24a1 was not significantly different between D2 and D3 mice, suggesting that 25D2 and 25D3 were not subject to different levels of catabolism. Interestingly, in both D2
and D3 mice, serum concentrations of 1,25D were significantly higher in wk16 versus wk8 mice.
The mechanism for this is unclear and does not appear to be due to any age-related changes in renal Cyp27b1 and/or Cyp24a1 expression.
The relative impact of 25D2 and 25D3 on serum concentrations of free 25D has been studied previously in human subjects supplemented with oral vitamin D2 or vitamin D3 at 1,000 IU/day for 3 months (34). In this instance, the subjects receiving vitamin D3 showed higher circulating levels of 25D and 1,25D at the end of the study, consistent with the data presented here for D3 versus D2 mice. In contrast to mouse data in the current study, human subjects supplemented with vitamin D2 showed lower levels of free or bioavailable (non-DBP bound) 25D relative to those supplemented with vitamin D3, although this effect was lost when data were adjusted for supplementation compliance (34). Other than species, the major difference between these two studies is that the mice described here received exclusively either D2 or D3 from weaning, and consequently their circulating 25D was made up entirely of either 25D2 or 25D3. In humans supplemented with D2 a significant proportion of 25D is made up of endogenously synthesized 25D3 obtained from cutaneous synthesis of vitamin D3 and vitamin D3 from food fortification. It
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was also notable that the human cohort study outlined above (34) involved elderly hip fracture patients, who were assessed only for changes in serum calcium relative to free 25D. We did not measure serum calcium in the D2 or D3 mice. However, there was no significant difference in serum PTH levels between these mice suggesting that differences in free 25D (at least at the levels found in these mice) is not a significant component of vitamin D-mediated regulation of parathyroid function and calcium homeostasis.
Although male and female D2 mice showed similar levels of total serum free 25D irrespective of age, the differential effects of 25D2 versus 25D3 were age and sex-dependent. The selection of week 8 and week 16 ages for assessment of bone phenotype was intended to capture data from the C57BL/6 mice at different stages of bone development: 1) at a young adult stage (week 8) when BV/TV is toward its peak; 2) at a mature adult state (week 16) when BV/TV begins to decline (35). At wk8, 25D2 was associated with enhanced osteoclastic and osteoblastic activity, but this effect was most pronounced in female mice. Temporal variations in bone development for male and female mice have been reported previously (35), and these observations may explain the differential effects of D2 and D3 demonstrated in the current study. Specifically, it is possible that osteoclast/osteoblast effects of free 25D are strongest in younger mice during active skeletal development, with these effects being lost later in life. This would also explain the stronger impact of D2 versus D3 in female mice, where changes in parameters of skeletal development tend to be slower than in male counterparts. In this setting greater bioavailability of 25D2 may promote stronger effects in females relative to 25D3 because of generally higher bone cell activity at females at this age point. As bone remodeling is the net effect of the activities of bone forming and bone resorbing cells, differences in bone structure will take longer to develop, and this may explain the significant differences in markers such as BV/TV, Tb.N and Tb. Sp for D2 versus D3 at week 16, but not at week 8.
Variable responses to 25D2 and 25D3 may not be restricted to the skeleton, as female D2 mice also exhibited differential effects on spleen gene expression and immune cell composition.
Previous reports have shown that the spleen serves as a reservoir for monocyte/macrophagelineage osteoclast precursors (OCP), which are generated and transferred to bone in response to diverse stimuli including vitamin D (36). Data presented here showed that D2 diet was associated with higher mRNA expression levels of monocyte/macrophage specific markers CD11b and RANKL, and also changes in the total monocyte population within spleen. Although further experiments must be completed in order to determine the specific cell subpopulations affected by D2 treatment, the results suggest a link between altered osteoblast/osteoclast markers in vitamin D2 vs D3 mice and the increase in OCP markers in the spleen. Therefore, the spleen may be a target tissue for the enhanced levels of free 25D observed in D2 mice.
Further in vivo studies using stimulated murine models will help elucidate whether these changes are more pronounced following immune challenge.
Studies in human subjects have reported better correlation with serum free 25D relative to total serum 25D for bone mineral density in healthy subjects (37), and serum markers of mineral homeostasis in renal dialysis patients (38). However, these data have not been consistent and recent data for bone density and mineral metabolism markers in healthy adults suggested that analysis of free 25D does not significantly improve correlations relative to conventional measurement of total serum (39). This may be due, in part, to existing strategies for calculating free or bioavailable 25D based on measurement of serum DBP levels, where discrepancies between ELISA analyses using monoclonal versus polyclonal antibodies have been described, support a role for free 25D in defining some parameters of skeletal function, it seems likely that extra-skeletal tissues will also be important targets for free 25D. Previous studies in vitro (16, 42) and spleen analyses reported here suggest that cells from the immune system may be strongly influenced by 25D that is not bound to DBP. As such, it will be interesting in future studies to determine whether, relative to vitamin D3, vitamin D2 supports enhanced immunomodulatory Table 2 Click here to download Table Table 2 
